Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 6/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19670409 | 0.88 | PRMT5 (0.42) | ATRLMNAGRM5MEN1KMT2A | |
| SCHEMBL19364834 | 0.88 | ALDH1A1 (0.39) | DYRK1AATRALDH1A1HDAC2NPC1 | |
| SCHEMBL19365309 | 0.88 | CNR2 (0.40) | ATRLMNAGRM5ALDH1A1HDAC3 | |
| SCHEMBL19365441 | 0.87 | ATR (0.48) | ATRLMNASMN1; SMN2KMT2AHDAC3 | |
| SCHEMBL19365471 | 0.87 | ATR (0.36) | DYRK1AATRLMNAGRM5ALDH1A1 | |
| SCHEMBL19365583 | 0.86 | ABL1 (0.38) | DYRK1AATRGRM5ALDH1A1HDAC2 | |
| SCHEMBL19670535 | 0.86 | GSK3B (0.38) | DYRK1AATRLMNAGRM5ALDH1A1 | |
| SCHEMBL19365794 | 0.85 | ATR (0.38) | ATRGRM5KMT2AALDH1A1NPC1 | |
| SCHEMBL19364825 | 0.85 | ATR (0.42) | ATRGRM5ALDH1A1HDAC3HDAC1 | |
| SCHEMBL19365302 | 0.84 | GSK3B (0.39) | DYRK1AATRGRM5HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | WNT1 3363/4885DYRK1A 2623/4885ATR 1867/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | WNT1 3363/4885DYRK1A 2623/4885ATR 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.